PhD in Clinical Microbiology, Medical School, National and Kapodistrian University of Athens
15
Scopus Publications
210
Scholar Citations
8
Scholar h-index
7
Scholar i10-index
Scopus Publications
Therapeutic application of a jumbo bacteriophage against metallo-β-lactamase producing Pseudomonas aeruginosa clinical isolates Paschalis Paranos, Dimitrios Skliros, Nikita Zrelovs, Panagiota-Christina Georgiou, Karina Svanberga, Andris Kazaks, Marios Kostakis, Nikolaos Thomaidis, Emmanouil Flemetakis, Joseph Meletiadis Journal of Biomedical Science, 2025 Background Therapeutic options against metallo-β-lactamase producing P. aeruginosa (MBL-PA) are limited due to multi-drug resistance. A jumbo phage isolated from wastewater in Greece was characterized microbiologically and genetically and evaluated for its potential as a therapeutic agent alone or in combination with antibiotics in an experimental thigh infection mouse model. Methods The host range of the jumbo phage vB_PaerM_AttikonH10 (AttikonH10) against 20 MBL-PA clinical isolates and 10 susceptible strains, one-step phage growth and growth curves of mid-exponential phase bacteria upon addition of the phage were analyzed. Whole-genome sequencing was performed and the de novo assembled complete phage genome was compared with other jumbo phages. In vivo pharmacokinetics in different tissues as well as the efficacy of two dosing regimens 109 and 106 PFU/mouse administered intraperitoneally alone and in combination with amikacin (384 mg/kg/day) was tested against an MBL-PA clinical isolate in murine thigh infection model. Results The phage formed small plaques in double-layer agar and demonstrated clear or semi-clear lysis in 83.3% (25/30) of P. aeruginosa clinical isolates. Growth curves showed a > 94% growth inhibition in the presence of phage even at the lowest multiplicity of infection ratio tested (10–5). Whole genome analysis indicated a jumbo dsDNA phage with 278,406 bp (36.92% GC) belonging to Phikzvirus that is predicted to host up to 413 putative ORFs and 6 tRNA genes. No known lysogeny-associated genes, virulence factors, or antimicrobial resistance genes were identified within the genome. Phage titres 104–106 PFU/tissue were detected in all mouse tissues with elimination half-life of 3.4 h except in bronchoalveolar lavage where no phages were found. Only the high phage dose (109 PFU/mouse) reduced bacterial load in thigh by 1.09 log10 cfu/thigh compared to placebo, similar to amikacin monotherapy (1.19 log10 cfu/thigh), while their combination achieved a greater reduction of 2.07 log10 cfu/thigh compared to each monotherapy (p = 0.0044–0.0048). Conclusions The newly reported Phikzvirus jumbo phage AttikonH10 demonstrated a broad host range, strong lytic activity and synergistic effects with amikacin against MBL-PA isolates making it a candidate for phage therapy.
Designing an effective phage cocktail against Klebsiella pneumoniae covering metallo-β-lactamases producing multi-drug resistant clinical isolates Paschalis Paranos, Dimitrios Skliros, Nikita Zrelovs, Panagiota-Christina Georgiou, Maria Siopi, Karina Svanberga, Andris Kazaks, Marios Kostakis, Nikolaos Thomaidis, Emmanouil Flemetakis, Joseph Meletiadis Microbial Pathogenesis, 2025 According to the ECDC in 2023, Greece presented a high rate of carbapenem-resistant Klebsiella pneumoniae (CRKP). Samples from the largest Athens’ sewage treatment plant (n = 50), rectal swabs (n = 50), and stool (n = 10) from ICU and pediatric patients were screened for phages using the double-layer agar method. Plaque morphology, genomic features, biological properties (host range, phage adsorption time and rate, latent period length and burst size) and growth inhibition kinetics were determined for all isolated phages. Phage tissue distribution and efficacy against a dominant ST11 CRKP clinical isolate were assessed in murine thigh infection model. A cocktail from different phages was designed based on biological characteristics and host range spectrum. In total 7 distinct bacteriophages were isolated from different samples 5 Drulisvirus , 1 Webevirus and 1 Przondovirus with varied lytic activity against 40 (18–50) % of all isolates in host-range studies and 51 (41–85) % growth inhibition at the lowest MOI 0.00001 in growth curve experiments. The median (range) adsorption rate, time, latent phase and burst size in one-step growth experiments were 94 (88–97) %, 6 (2–10) min, 25 (15–40) min, and 63 (47–160) PFU/infected cell, respectively. Phages were rapidly distributed in different organs with high titers up to 8h and a 4log bacterial load reduction was found with the highest dose 10 9 PFU/mouse. A cocktail of 5 phages was effective against 87.5 % of ESBL, NDM and VIM-producing isolates. Several phages with potent lytic activity and different host spectrum range against CRKP isolates were found. The 5-phage cocktail could be used for phage therapy of CRKP infections. • Seven lytic bacteriophages against carbapenem-resistant Klebsiella pneumoniae were isolated. • Host-range spectrum was 40 % (18 %–50 %) with up to 85 % growth inhibition at low phage concentrations. • In vivo phages were rapidly distributed in different organs in a thigh infection model. • A 4log kill compared to control was found with the highest phage dose 10 9 PFU/mouse. • A cocktail of 5 phages was effective against 87.5 % of ESBL, NDM and VIM-producing isolates.
Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations Paschalis Paranos, Maria Siopi, Eleni Papanikolaou, Sophia Vourli, Panagoula Kolia, Spyros Pournaras, Joseph Meletiadis Journal of Antimicrobial Chemotherapy, 2025 Background Therapeutic options for MDR carbapenemase-producing Klebsiella pneumoniae (CRKP) are limited. We therefore assessed the in vitro activity of five antibiotics from different classes in combination with lytic bacteriophages (phages) against MDR CRKP isolates. Material and methods A total of 15 non-repetitive, well-characterized MDR CRKP isolates and four phages belonging to the Podoviridae family were used in chequerboard assays with amikacin, meropenem, ciprofloxacin, colistin and ceftazidime/avibactam. The spectrophotometrically determined MIC of drugs and phages alone and in combination were used to calculate the fractional inhibitory concentration index (FICi). The clinical relevance was assessed based on the MIC reductions at clinically achievable concentrations and below the corresponding susceptibility breakpoints. Emergence of resistance was studied in growth curves and time–kill experiments. Results Synergy was found for ciprofloxacin in 6/15 (40%) isolates, meropenem in 10/15 (67%), ceftazidime/avibactam in 11/15 (73%), colistin in 8/15 (53%) and amikacin in 9/15 (60%) with all four phages against host bacteria. The synergistic interactions were strong as the FICi were 0.01–0.35 reducing the MICs (>90% growth inhibition) to clinically achievable concentrations for 87%–100% of strains, except ciprofloxacin. Reversal of phenotypic resistance was observed for amikacin, meropenem, colistin and ceftazidime/avibactam in 100%, 53%, 89% and 80% of isolates, respectively. No emergence of resistance was found for isolates with low level resistance to amikacin (MΙC 64 mg/L). Conclusions The phage–antibiotic combinations were synergistic against more than half of the isolates for all antibiotics except ciprofloxacin reversing resistance in most strains particularly with amikacin.
In Vitro Interactions Between Bacteriophages and Antibacterial Agents of Various Classes Against Multidrug-Resistant Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Clinical Isolates Paschalis Paranos, Sophia Vourli, Spyros Pournaras, Joseph Meletiadis Pharmaceuticals, 2025 Background: Combination therapy with antibiotics and phages has been suggested to increase the antibacterial activity of both antibiotics and phages. We tested the in vitro activity of five antibiotics belonging to different classes in combination with lytic bacteriophages against multidrug-resistant metallo-β-lactamase (MBL)-producing Pseudomonas aeruginosa isolates. Material/Methods: A total of 10 non-repetitive well-characterized MBL-producing P. aeruginosa isolates (5 NDM, 5 VIM) co-resistant to aminoglycosides and quinolones were used. Phage–antibiotic interactions were assessed using an ISO-20776-based broth microdilution checkerboard assay in 96-well microtitration plates. Two-fold dilutions of colistin (8–0.125 mg/L), ciprofloxacin, meropenem, aztreonam, and amikacin (256–4 mg/L) were combined with ten-fold dilutions of five different phages (5 × 109–5 × 100 PFU/mL) belonging to Pakpunavirus, Phikzvirus, Pbunavirus, and Phikmvvirus genus. Plates were incubated at 35 ± 2 °C for 24 h, and the minimum inhibitory concentration of antibiotics (MICA) and phages (MICP) were determined as the lowest drug and phage concentration, resulting in <10% growth based on photometric reading at 550 nm. Interactions were assessed based on the fractional inhibitory concentration index (FICi) of three independent replicates and clinical relevance based on the reversal of phenotypic resistance. The statistical significance of each drug alone and in combination with phages was assessed using GraphPad Prism 8.0. Results: Synergistic and additive interactions were found for 60–80% of isolates for all drugs. FICis were statistically significantly lower than 0.5 for colistin (p = 0.005), ciprofloxacin (p = 0.02), meropenem (p = 0.003), and amikacin (p = 0.002). Interactions were found at clinically achievable concentrations for colistin, meropenem, and amikacin, and a reversal of phenotypic resistance was observed for most strains (63–64%) for amikacin and meropenem. Antagonism was found for few isolates with all antibiotics tested. Phage vB_PaerM_AttikonH10 and vB_PaerP_AttikonH4 belonging to Phikzvirus and Phikmvvirus genus, respectively, showed either synergistic (FICi ≤ 0.35) or additive effects with most antibiotics tested. Conclusions: Synergy was observed for most drugs and phages with amikacin, showing strong synergy and reversal of phenotypic resistance against most isolates. Taking into account the wide utility of jumbo phages obtained, the findings of vB_PaerM_AttikonH10 in combination with different classes of antibiotics can enhance the activity of currently ineffective antibiotics against MBL-producing P. aeruginosa isolates.
Detection of Phage’s Lytic Activity Against Carbapenemase-Producing Klebsiella pneumoniae Isolates Using a High-Throughput Microbroth Growth Inhibition Assay Paschalis Paranos, Spyros Pournaras, Joseph Meletiadis Infectious Diseases and Therapy, 2025 The host range of phages is usually assessed with the agar overlay method. However, this method is both cumbersome and subjective. Therefore, a microbroth assay was developed to assess host range and lytic activity patterns of phages in the agar overlay method against a collection of carbapenemase-producing Klebsiella pneumoniae (CRKP) isolates. The host range of 11 K. pneumoniae -specific phages against 8 non-repetitive well-characterized CRKP isolates was assessed with the agar overlay method and a microbroth assay by monitoring optical density (OD) at 630 nm for 24 h at different phage concentrations (5 × 10 9 –5 × 10 3 PFU/ml) and two bacterial inocula (5 × 10 6 and 5 × 10 8 CFU/ml). The lytic activity of phage–bacteria pairs with transparent/semi-transparent ( N = 7), turbid ( N = 6), and no ( N = 6) lysis in overlay agar method was compared statistically with the growth inhibition at 6 and 24 h in the microbroth assay with analysis of variance (ANOVA), receiver operating characteristic curves (ROC) curves and Fisher’s exact test. Optimal cutoffs were determined, and sensitivity and specificity were calculated. Statistically significant differences of growth inhibition at 6 and 24 h for phage concentrations ≥ 5 × 10 8 PFU/ml for both inocula were found between phages with transparent/semi-transparent, turbid, and no lysis. ROC curve analysis indicated an optimal growth inhibition cutoff of ≥ 31% at high phage and bacteria concentrations for detecting phages with lysis and ≥ 61% at high-phage and low-bacteria concentrations for detecting phages with transparent/semi-transparent lysis with sensitivity/specificity 100%/100% and 100%/86%, respectively. The microbroth growth inhibition assay provided fast, reliable, and objective results for K. pneumoniae phage host-range lytic activity differentiating different patterns of lysis in a high-throughput format.
Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections Maria Siopi, Dimitrios Skliros, Paschalis Paranos, Nikoletta Koumasi, Emmanouil Flemetakis, Spyros Pournaras, Joseph Meletiadis Clinical Microbiology Reviews, 2024 SUMMARY Despite the early recognition of their therapeutic potential and the current escalation of multidrug-resistant (MDR) pathogens, the adoption of bacteriophages into mainstream clinical practice is hindered by unfamiliarity with their basic pharmacokinetic (PK) and pharmacodynamic (PD) properties, among others. Given the self-replicative nature of bacteriophages in the presence of host bacteria, the adsorption rate, and the clearance by the host’s immunity, their PK/PD characteristics cannot be estimated by conventional approaches, and thus, the introduction of new considerations is required. Furthermore, the multitude of different bacteriophage types, preparations, and treatment schedules impedes drawing general conclusions on their in vivo PK/PD features. Additionally, the drawback of acquired bacteriophage resistance of MDR pathogens with clinical and environmental implications should be taken into consideration. Here, we provide an overview of the current state of the field of PK and PD of bacteriophage therapy with a focus on its application against MDR Gram-negative infections, highlighting the potential knowledge gaps and the challenges in translation from the bench to the bedside. After reviewing the in vitro PKs and PDs of bacteriophages against the four major MDR Gram-negative pathogens, Klebsiella pneumoniae , Acinetobacter baumannii complex, Pseudomonas aeruginosa , and Escherichia coli , specific data on in vivo PKs (tissue distribution, route of administration, and basic PK parameters in animals and humans) and PDs (survival and reduction of bacterial burden in relation to the route of administration, timing of therapy, dosing regimens, and resistance) are summarized. Currently available data merit close scrutiny, and optimization of bacteriophage therapy in the context of a better understanding of the underlying PK/PD principles is urgent to improve its therapeutic effect and to minimize the occurrence of bacteriophage resistance.
Increase in candidemia cases and emergence of fluconazole-resistant Candida parapsilosis and C. auris isolates in a tertiary care academic hospital during the COVID-19 pandemic, Greece, 2020 to 2023 Maria Siopi, Panagiota-Christina Georgiou, Paschalis Paranos, Maria-Ioanna Beredaki, Aikaterini Tarpatzi, Eleni Kalogeropoulou, Sofia Damianidou, Alexandra Vasilakopoulou, Polyxeni Karakosta, Spyros Pournaras, Joseph Meletiadis Eurosurveillance, 2024 Background The COVID-19 pandemic and the emergence of Candida auris have changed the epidemiological landscape of candidaemia worldwide. Aim We compared the epidemiological trends of candidaemia in a Greek tertiary academic hospital before (2009–2018) and during the early COVID-19 (2020–2021) and late COVID-19/early post-pandemic (2022–2023) era. Methods Incidence rates, species distribution, antifungal susceptibility profile and antifungal consumption were recorded, and one-way ANOVA or Fisher’s exact test performed. Species were identified by MALDI-ToF MS, and in vitro susceptibility determined with CLSI M27-Ed4 for C. auris and the EUCAST-E.DEF 7.3.2 for other Candida spp. Results In total, 370 candidaemia episodes were recorded during the COVID-19 pandemic. Infection incidence (2.0 episodes/10,000 hospital bed days before, 3.9 during the early and 5.1 during the late COVID-19 era, p < 0.0001), C. auris (0%, 9% and 33%, p < 0.0001) and fluconazole-resistant C. parapsilosis species complex (SC) (20%, 24% and 33%, p = 0.06) infections increased over time, with the latter not associated with increase in fluconazole/voriconazole consumption. A significant increase over time was observed in fluconazole-resistant isolates regardless of species (8%, 17% and 41%, p < 0.0001). Resistance to amphotericin B or echinocandins was not recorded, with the exception of a single pan-echinocandin-resistant C. auris strain. Conclusion Candidaemia incidence nearly tripled during the COVID-19 era, with C. auris among the major causative agents and increasing fluconazole resistance in C. parapsilosis SC. Almost half of Candida isolates were fluconazole-resistant, underscoring the need for increased awareness and strict implementation of infection control measures.
Commercial Methods for Antifungal Susceptibility Testing of Saprophytic Molds: Can They Be Used to Detect Resistance? Paschalis Paranos, Ana Espinel-Ingroff, Joseph Meletiadis Journal of Fungi, 2024 Commercial tests are often employed in clinical microbiology laboratories for antifungal susceptibility testing of filamentous fungi. Method-dependent epidemiological cutoff values (ECVs) have been defined in order to detect non-wild-type (NWT) isolates harboring resistance mechanisms. We reviewed the literature in order to find studies where commercial methods were used to evaluate for in vitro susceptibility of filamentous fungi and assess their ability to detect NWT isolates according to the available ECVs. Data were found for the gradient concentration strips Etest and MIC Test Strips (MTS), broth microdilution Sensititre YeastOne (SYO), Micronaut-AM and the agar dilution VIPcheck assays. Applying itraconazole, voriconazole and posaconazole Etest ECVs for A. fumigatus, Etest was able to detect 90.3% (84/93), 61.2% (90/147) and 86% (31/36) of isolates with known cyp51A mutations, respectively. Moreover, Etest also was able to detect 3/3 fks mutants using caspofungin ECVs and 2/3 micafungin mutant isolates. Applying the voriconazole and posaconazole SYO ECVs, 57.7% (67/116) and 100% (47/47) of mutants with known cyp51A substitutions were classified as NWT, respectively. VIPcheck detected 90.3% (159/176), 80.1% (141/176) and 66% (141/176)of mutants via itraconazole, voriconazole and posaconazole, respectively, whereas Micronaut-AM detected 88% (22/25). In conclusion, Etest posaconazole and itraconazole, as well as micafungin and caspofungin ECVs, detected A. fumigatus mutants. On the other hand, while the posaconazole SYO ECV was able to detect cyp51A mutants, similar data were not observed with the SYO voriconazole ECV.
A single-layer spot assay for easy, fast, and high-throughput quantitation of phages against multidrug-resistant Gram-negative pathogens Paschalis Paranos, Spyros Pournaras, Joseph Meletiadis Journal of Clinical Microbiology, 2024 Double-layer agar (DLA) overlay plaque assay is the gold standard for phage enumeration. However, it is cumbersome and time-consuming. Given the great interest in phage therapy, we explored alternative assays for phage quantitation. A total of 16 different phages belonging to Myoviridae, Siphoviridae, and Podoviridae families were quantitated with five K . pneumoniae, eight P . aeruginosa, and three A . baumannii host isolates. Phages were quantitated with the standard DLA assay (10 mL of LB soft agar 0.7% on LB hard agar 1.5%) and the new single-layer agar (SLA) assay (10 mL of LB soft agar 0.7%) with phages spread (spread) into or spotted (spot) onto soft agar. Phage concentrations with each assay were correlated with the standard assay, and the relative and absolute differences between each assay and the standard double-layer agar spread were calculated. Phage concentrations 1 × 10 4 –8.3 x10 12 PFU/mL with the standard DLA assay were quantitated with SLA-spread, SLA-spot, and DLA-spot assays, and the median (range) relative and absolute differences were <10% and <0.98 log 10 PFU/mL, respectively, for all phage/bacterial species (ANOVA P = 0.1–0.43), and they were highly correlated (r > 0.77, P < 0.01). Moreover, plaques could be quantified at 37°C after 4-h incubation for K. pneumoniae phages and 6-h incubation for P. aeruginosa and A. baumannii phages, and estimated concentrations remained the same over 24 hours. Compared to DLA assay, the SLA-spot assay required less media, it was 10 times faster, and generated same-day results. The SLA-spot assay was cheaper, faster, easier to perform, and generated similar phage concentrations as the standard DLA-spread assay.
Publisher Correction: Therapeutic application of a jumbo bacteriophage against metallo-β-lactamase producing Pseudomonas aeruginosa clinical isolates P Paranos, D Skliros, N Zrelovs, PC Georgiou, K Svanberga, A Kazaks, ... Journal of Biomedical Science 32, 105 , 2025 2025
Designing an effective phage cocktail against Klebsiella pneumoniae covering metallo-β-lactamases producing multi-drug resistant clinical isolates P Paranos, D Skliros, N Zrelovs, PC Georgiou, M Siopi, K Svanberga, ... Microbial pathogenesis 208, 107926 , 2025 2025 Citations: 4
Therapeutic application of a jumbo bacteriophage against metallo-β-lactamase producing Pseudomonas aeruginosa clinical isolates P Paranos, D Skliros, N Zrelovs, PC Georgiou, K Svanberga, A Kazaks, ... Journal of Biomedical Science 32 (1), 74 , 2025 2025 Citations: 6
Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between … P Paranos, M Siopi, E Papanikolaou, S Vourli, P Kolia, S Pournaras, ... Journal of Antimicrobial Chemotherapy 80 (7), 1997-2006 , 2025 2025 Citations: 2
In vitro interactions between bacteriophages and antibacterial agents of various classes against multidrug-resistant metallo-β-lactamase-producing Pseudomonas aeruginosa … P Paranos, S Vourli, S Pournaras, J Meletiadis Pharmaceuticals 18 (3), 343 , 2025 2025 Citations: 9
Combination therapy of bacteriophages and antibacterial drugs against multidrug-resistant Pseudomonas aeruginosa P Paranos Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ). Σχολή Επιστημών Υγείας … , 2025 2025
Detection of Phage’s Lytic Activity Against Carbapenemase-Producing Klebsiella pneumoniae Isolates Using a High-Throughput Microbroth Growth Inhibition Assay P Paranos, S Pournaras, J Meletiadis Infectious Diseases and Therapy 14 (1), 217-228 , 2025 2025 Citations: 5
Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections M Siopi, D Skliros, P Paranos, N Koumasi, E Flemetakis, S Pournaras, ... Clinical Microbiology Reviews 37 (3), e00044-24 , 2024 2024 Citations: 34
A single-layer spot assay for easy, fast, and high-throughput quantitation of phages against multidrug-resistant Gram-negative pathogens P Paranos, S Pournaras, J Meletiadis Journal of Clinical Microbiology 62 (8), e00743-24 , 2024 2024 Citations: 19
Increase in candidemia cases and emergence of fluconazole-resistant Candida parapsilosis and C. auris isolates in a tertiary care academic hospital during the COVID-19 pandemic … M Siopi, PC Georgiou, P Paranos, MI Beredaki, A Tarpatzi, ... Eurosurveillance 29 (29), 2300661 , 2024 2024 Citations: 28
Severe mold fungal infections in critically ill patients with COVID-19 D Koulenti, E Paramythiotou, MP Almyroudi, M Karvouniaris, N Markou, ... Future Microbiology 19 (9), 825-840 , 2024 2024 Citations: 5
Commercial methods for antifungal susceptibility testing of saprophytic molds: can they be used to detect resistance? P Paranos, A Espinel-Ingroff, J Meletiadis Journal of Fungi 10 (3), 214 , 2024 2024 Citations: 11
Severe Candida infections in critically ill patients with COVID-19 D Koulenti, M Karvouniaris, E Paramythiotou, N Koliakos, N Markou, ... Journal of intensive medicine 3 (04), 291-297 , 2023 2023 Citations: 24
Assessing clinical potential of old antibiotics against severe infections by multi-drug-resistant gram-negative bacteria using in silico modelling P Paranos, S Vourli, S Pournaras, J Meletiadis Pharmaceuticals 15 (12), 1501 , 2022 2022 Citations: 14
Pharmacodynamics of colistin resistance in carbapenemase-producing Klebsiella pneumoniae : the double-edged sword of heteroresistance and adaptive resistance J Meletiadis, P Paranos, M Tsala, S Pournaras, S Vourli Journal of medical microbiology 71 (10), 001565 , 2022 2022 Citations: 6
In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas … J Meletiadis, P Paranos, PC Georgiou, S Vourli, S Antonopoulou, ... International journal of antimicrobial agents 58 (5), 106440 , 2021 2021 Citations: 43
MOST CITED SCHOLAR PUBLICATIONS
In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas … J Meletiadis, P Paranos, PC Georgiou, S Vourli, S Antonopoulou, ... International journal of antimicrobial agents 58 (5), 106440 , 2021 2021 Citations: 43
Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections M Siopi, D Skliros, P Paranos, N Koumasi, E Flemetakis, S Pournaras, ... Clinical Microbiology Reviews 37 (3), e00044-24 , 2024 2024 Citations: 34
Increase in candidemia cases and emergence of fluconazole-resistant Candida parapsilosis and C. auris isolates in a tertiary care academic hospital during the COVID-19 pandemic … M Siopi, PC Georgiou, P Paranos, MI Beredaki, A Tarpatzi, ... Eurosurveillance 29 (29), 2300661 , 2024 2024 Citations: 28
Severe Candida infections in critically ill patients with COVID-19 D Koulenti, M Karvouniaris, E Paramythiotou, N Koliakos, N Markou, ... Journal of intensive medicine 3 (04), 291-297 , 2023 2023 Citations: 24
A single-layer spot assay for easy, fast, and high-throughput quantitation of phages against multidrug-resistant Gram-negative pathogens P Paranos, S Pournaras, J Meletiadis Journal of Clinical Microbiology 62 (8), e00743-24 , 2024 2024 Citations: 19
Assessing clinical potential of old antibiotics against severe infections by multi-drug-resistant gram-negative bacteria using in silico modelling P Paranos, S Vourli, S Pournaras, J Meletiadis Pharmaceuticals 15 (12), 1501 , 2022 2022 Citations: 14
Commercial methods for antifungal susceptibility testing of saprophytic molds: can they be used to detect resistance? P Paranos, A Espinel-Ingroff, J Meletiadis Journal of Fungi 10 (3), 214 , 2024 2024 Citations: 11
In vitro interactions between bacteriophages and antibacterial agents of various classes against multidrug-resistant metallo-β-lactamase-producing Pseudomonas aeruginosa … P Paranos, S Vourli, S Pournaras, J Meletiadis Pharmaceuticals 18 (3), 343 , 2025 2025 Citations: 9
Therapeutic application of a jumbo bacteriophage against metallo-β-lactamase producing Pseudomonas aeruginosa clinical isolates P Paranos, D Skliros, N Zrelovs, PC Georgiou, K Svanberga, A Kazaks, ... Journal of Biomedical Science 32 (1), 74 , 2025 2025 Citations: 6
Pharmacodynamics of colistin resistance in carbapenemase-producing Klebsiella pneumoniae : the double-edged sword of heteroresistance and adaptive resistance J Meletiadis, P Paranos, M Tsala, S Pournaras, S Vourli Journal of medical microbiology 71 (10), 001565 , 2022 2022 Citations: 6
Detection of Phage’s Lytic Activity Against Carbapenemase-Producing Klebsiella pneumoniae Isolates Using a High-Throughput Microbroth Growth Inhibition Assay P Paranos, S Pournaras, J Meletiadis Infectious Diseases and Therapy 14 (1), 217-228 , 2025 2025 Citations: 5
Severe mold fungal infections in critically ill patients with COVID-19 D Koulenti, E Paramythiotou, MP Almyroudi, M Karvouniaris, N Markou, ... Future Microbiology 19 (9), 825-840 , 2024 2024 Citations: 5
Designing an effective phage cocktail against Klebsiella pneumoniae covering metallo-β-lactamases producing multi-drug resistant clinical isolates P Paranos, D Skliros, N Zrelovs, PC Georgiou, M Siopi, K Svanberga, ... Microbial pathogenesis 208, 107926 , 2025 2025 Citations: 4
Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between … P Paranos, M Siopi, E Papanikolaou, S Vourli, P Kolia, S Pournaras, ... Journal of Antimicrobial Chemotherapy 80 (7), 1997-2006 , 2025 2025 Citations: 2
Publisher Correction: Therapeutic application of a jumbo bacteriophage against metallo-β-lactamase producing Pseudomonas aeruginosa clinical isolates P Paranos, D Skliros, N Zrelovs, PC Georgiou, K Svanberga, A Kazaks, ... Journal of Biomedical Science 32, 105 , 2025 2025
Combination therapy of bacteriophages and antibacterial drugs against multidrug-resistant Pseudomonas aeruginosa P Paranos Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ). Σχολή Επιστημών Υγείας … , 2025 2025
